EU suspension for Servier's Protelos on the cards
This article was originally published in Scrip
Executive Summary
The EU's pharmacovigilance committee PRAC has recommended to the CHMP that the marketing authorization for Servier's osteoporosis drug Protelos/Osseor (strontium ranelate) be suspended. The product's fate now awaits the CHMP's next meeting on 20-23 January.